2024-11-15 - Analysis Report
## Eli Lilly and Co (LLY) Stock Analysis:

### 1. Performance vs. S&P 500:

Eli Lilly and Co (LLY) is a pharmaceutical company that develops and manufactures pharmaceutical products. 

LLY has significantly outperformed the S&P 500 (VOO) with a cumulative return of **916.12%** compared to **179.47%** for the S&P 500. This represents a **736.65%** difference in cumulative returns. 

The relative divergence of **77.95%** indicates that LLY has been outperforming the S&P 500 over a longer period compared to the historical range.  

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|-------|------|-------|
| 2015-2017  | 30.4% | 18.8% | -8.0% | 0.8 | 80.2 |
| 2016-2018  | 50.8% | 18.8% | 18.5% | 0.7 | 109.8 |
| 2017-2019  | 89.5% | 16.8% | 37.8% | 0.7 | 124.8 |
| 2018-2020  | 113.2% | 21.9% | 65.8% | 0.7 | 160.3 |
| 2019-2021  | 154.6% | 21.9% | 54.6% | 0.7 | 262.2 |
| 2020-2022  | 190.4% | 21.9% | 166.8% | 0.7 | 347.3 |
| 2021-2023  | 266.0% | 18.6% | 231.1% | 0.5 | 553.4 |
| 2022-2024  | 207.3% | 19.0% | 176.9% | 0.6 | 777.4 |


* **CAGR:** Compound Annual Growth Rate 
* **MDD:** Maximum Drawdown
* **Alpha:** Excess return compared to the benchmark (S&P 500)
* **Beta:** Volatility relative to the market
* **Cap(B):** Market capitalization in Billions of dollars

The analysis shows LLY has generally outperformed the S&P 500 with a higher CAGR and strong alpha. However, the beta suggests it's less volatile than the market, which can be a positive for risk-averse investors.


### 2. Recent Price Movement:

* Closing price: $811.81 
* Last market price: $790.7
* 5-day moving average: $818.42
* 20-day moving average: $855.65
* 60-day moving average: $898.79

The stock is currently trading below its moving averages, which indicates a potential short-term downtrend. However, the last market price is lower than the closing price, implying a potential rebound.


### 3. Technical Indicators:

* **RSI:** 31.61 (below 30 indicates oversold) 
* **PPO:** -0.31 (negative value indicates bearish momentum)
* **Delta_Previous_Relative_Divergence:** -14.56 (-)  (short-term downtrend) 
* **Expected_Return:** 116.37% (This indicates a potential for significant long-term outperformance compared to the S&P 500)

These indicators suggest a potential for short-term volatility and a potential for a rebound. The high expected return indicates a long-term positive outlook.

### 4. Recent Earnings and Outlook:

| Date       | EPS   | Revenue |
|---|---|---|
| 2024-10-30 | $1.08 | $11.44 B |
| 2024-08-08 | $3.29 | $11.30 B |
| 2024-04-30 | $2.49 | $8.77 B |
| 2023-11-02 | -$0.06 | $9.50 B |
| 2024-10-30 | -$0.06 | $9.50 B |

The most recent earnings report shows EPS of $1.08 and revenue of $11.44B. The results are expected to be discussed in more detail in the company's next earnings call. 

### 5. Financial Information:

**1) Revenue and Profitability:**

| Quarter       | Revenue     | Profit Margin |
|---|---|---|
| 2024-09-30 | $11.44B | 81.02% |
| 2024-06-30 | $11.30B | 80.80% |
| 2024-03-31 | $8.77B  | 80.91% |
| 2023-12-31 | $9.35B  | 80.88% |
| 2023-09-30 | $9.50B  | 80.42% |

LLY maintains consistent and strong revenue growth and high profitability. 

**2) Capital and Profitability:**

| Quarter       | Equity     | ROE    |
|---|---|---|
| 2024-09-30 | $14.24B | 6.81% |
| 2024-06-30 | $13.56B | 21.88% |
| 2024-03-31 | $12.81B | 17.51% |
| 2023-12-31 | $10.77B | 20.33% |
| 2023-09-30 | $11.22B | -0.51% |

The data shows a strong equity position and generally good ROE, though there's a notable drop in Q3 2023. 

### 6. News and Recent Issues:

* **Recent Earnings News:**  A thorough search on Shacknews, and other financial news outlets did not find any recent earnings news for LLY within the last 2 days. 
* **Analyst Opinions:** FINBOLD reports that the recent market outlook for LLY is positive, with analysts generally bullish on the stock. The company's strong performance in key areas like diabetes treatments and the launch of new products like Donanemab are cited as potential growth drivers.
* **Performance Highlights:** LLY is currently considered a strong performer in the pharmaceutical sector. Its focus on innovation and new treatments is driving strong revenue growth and profitability. 


### 7. Conclusion: 

LLY is a solid investment choice with a strong track record of outperforming the market. The company's strong financial performance, positive market outlook, and innovative pipeline of products suggest a continued growth trajectory. Despite recent market volatility and a slight pullback in share price, LLY remains a compelling investment opportunity, particularly for long-term investors seeking exposure to the pharmaceutical sector. 

### 8. Recommendations:

* **Long-term investors:** LLY is a solid long-term investment option with strong fundamentals and potential for significant growth.
* **Short-term investors:** The current pullback in share price may present an opportunity for short-term entry, however, the stock may be volatile in the near term.

**Please note:** This analysis is based on available publicly available data and is for informational purposes only. It is not intended as investment advice. Before making any investment decisions, please consult with a qualified financial professional. 
